What is the projected market valuation of the Infectious Disease Treatments Market by 2035?

The market is projected to reach approximately 132.29 USD Billion by 2035. Read More

What was the market valuation of the Infectious Disease Treatments Market in 2024?

In 2024, the market valuation stood at 62.15 USD Billion. Read More

What is the expected CAGR for the Infectious Disease Treatments Market from 2025 to 2035?

The expected CAGR during the forecast period 2025 - 2035 is 7.11%. Read More

Which companies are considered key players in the Infectious Disease Treatments Market?

Key players include Pfizer, Johnson & Johnson, Merck & Co., Gilead Sciences, AstraZeneca, Novartis, Roche, Sanofi, and Bristol-Myers Squibb. Read More

What are the projected revenues for viral diseases in the Infectious Disease Treatments Market by 2035?

Projected revenues for viral diseases are expected to reach 52.0 USD Billion by 2035. Read More

How do antibacterial drugs perform in the Infectious Disease Treatments Market?

Antibacterial drugs are projected to generate revenues of 42.0 USD Billion by 2035. Read More

What is the expected revenue for hospitals and clinics as end users in the market by 2035?

Revenues from hospitals and clinics as end users are anticipated to reach 55.0 USD Billion by 2035. Read More

What is the projected market size for antifungal drugs by 2035?

The market size for antifungal drugs is expected to reach 20.0 USD Billion by 2035. Read More

What segment is expected to show the highest growth in the Infectious Disease Treatments Market?

The segment for others in the treatment category is projected to grow to 25.29 USD Billion by 2035. Read More

What is the anticipated revenue for chronic obstructive pulmonary disease (COPD) treatments by 2035?

Anticipated revenues for COPD treatments are expected to reach 34.0 USD Billion by 2035. Read More

Infectious Disease Treatments Market

ID: MRFR/Pharma/1095-HCR

90 Pages

Satyendra Maurya

Last Updated: April 06, 2026

Infectious Disease Treatments Market Research Report Information By Type (Viral Diseases, Bacterial Diseases) Treatment (Antibacterial, Antifungal Drugs, Antiviral Drugs) End Users (Hospitals & Clinics, Retail Pharmacies) - Forecast till 2035

Infectious Disease Treatments Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.11%

2024 Market Size$ 62.15 Billion

2025 Market Size$ 66.56 Billion

2035 Market Size$ 132.29 Billion

Key Players

Pfizer

Johnson & Johnson

Merck & Co.

Gilead Sciences

AstraZeneca

Novartis

Trends

Rise of Personalized Medicine
Advancements in Antimicrobial Research
Integration of Digital Health Solutions

Opportunities

Emergence of Antimicrobial Resistance
Increasing Incidence of Infectious Diseases
Rising Investment in Healthcare Infrastructure

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Viral Diseases
  2. 4.1.2 Bacterial Diseases
  3. 4.1.3 Others
2. 4.2 Healthcare, BY Treatment (USD Billion)
  1. 4.2.1 Antibacterial Drugs
  2. 4.2.2 Antifungal Drugs
  3. 4.2.3 Antiviral Drugs
  4. 4.2.4 Anti-parasitic Drugs
  5. 4.2.5 Others
3. 4.3 Healthcare, BY Application (USD Billion)
  1. 4.3.1 Asthma
  2. 4.3.2 Chronic Obstructive Pulmonary Disease (COPD)
  3. 4.3.3 Cystic Fibrosis
  4. 4.3.4 Others
4. 4.4 Healthcare, BY End Users (USD Billion)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Research Organization
  3. 4.4.3 Retail Pharmacies
  4. 4.4.4 Others
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Johnson & Johnson (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bristol-Myers Squibb (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY APPLICATION
6. 6.6 US MARKET ANALYSIS BY END USERS
7. 6.7 CANADA MARKET ANALYSIS BY TYPE
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT
9. 6.9 CANADA MARKET ANALYSIS BY APPLICATION
10. 6.10 CANADA MARKET ANALYSIS BY END USERS
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT
14. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
15. 6.15 GERMANY MARKET ANALYSIS BY END USERS
16. 6.16 UK MARKET ANALYSIS BY TYPE
17. 6.17 UK MARKET ANALYSIS BY TREATMENT
18. 6.18 UK MARKET ANALYSIS BY APPLICATION
19. 6.19 UK MARKET ANALYSIS BY END USERS
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT
22. 6.22 FRANCE MARKET ANALYSIS BY APPLICATION
23. 6.23 FRANCE MARKET ANALYSIS BY END USERS
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT
26. 6.26 RUSSIA MARKET ANALYSIS BY APPLICATION
27. 6.27 RUSSIA MARKET ANALYSIS BY END USERS
28. 6.28 ITALY MARKET ANALYSIS BY TYPE
29. 6.29 ITALY MARKET ANALYSIS BY TREATMENT
30. 6.30 ITALY MARKET ANALYSIS BY APPLICATION
31. 6.31 ITALY MARKET ANALYSIS BY END USERS
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT
34. 6.34 SPAIN MARKET ANALYSIS BY APPLICATION
35. 6.35 SPAIN MARKET ANALYSIS BY END USERS
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USERS
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE
42. 6.42 CHINA MARKET ANALYSIS BY TREATMENT
43. 6.43 CHINA MARKET ANALYSIS BY APPLICATION
44. 6.44 CHINA MARKET ANALYSIS BY END USERS
45. 6.45 INDIA MARKET ANALYSIS BY TYPE
46. 6.46 INDIA MARKET ANALYSIS BY TREATMENT
47. 6.47 INDIA MARKET ANALYSIS BY APPLICATION
48. 6.48 INDIA MARKET ANALYSIS BY END USERS
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT
51. 6.51 JAPAN MARKET ANALYSIS BY APPLICATION
52. 6.52 JAPAN MARKET ANALYSIS BY END USERS
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USERS
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT
59. 6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USERS
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT
63. 6.63 THAILAND MARKET ANALYSIS BY APPLICATION
64. 6.64 THAILAND MARKET ANALYSIS BY END USERS
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT
67. 6.67 INDONESIA MARKET ANALYSIS BY APPLICATION
68. 6.68 INDONESIA MARKET ANALYSIS BY END USERS
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT
71. 6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USERS
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT
76. 6.76 BRAZIL MARKET ANALYSIS BY APPLICATION
77. 6.77 BRAZIL MARKET ANALYSIS BY END USERS
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT
80. 6.80 MEXICO MARKET ANALYSIS BY APPLICATION
81. 6.81 MEXICO MARKET ANALYSIS BY END USERS
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT
84. 6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USERS
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USERS
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USERS
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USERS
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT
101. 6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USERS
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USERS, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USERS, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USERS, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.3.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USERS, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.4.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USERS, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.5.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USERS, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.6.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USERS, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.7.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USERS, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.8.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USERS, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.9.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USERS, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.10.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USERS, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.11.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USERS, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.12.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USERS, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.13.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USERS, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.14.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USERS, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.15.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USERS, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.16.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USERS, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.17.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USERS, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.18.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USERS, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.19.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USERS, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.20.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USERS, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.21.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USERS, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.22.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USERS, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.23.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USERS, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.24.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USERS, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.25.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USERS, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.26.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USERS, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.27.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USERS, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.28.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USERS, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.29.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USERS, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY TREATMENT, 2025-2035 (USD Billion)
  3. 7.30.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USERS, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Infectious Disease Treatments Market Segmentation

Infectious Disease Treatments Market By Type (USD Billion, 2025-2035)

Viral Diseases
Bacterial Diseases
Others

Infectious Disease Treatments Market By Treatment (USD Billion, 2025-2035)

Antibacterial Drugs
Antifungal Drugs
Antiviral Drugs
Anti-parasitic Drugs
Others

Infectious Disease Treatments Market By Application (USD Billion, 2025-2035)

Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Cystic Fibrosis
Others

Infectious Disease Treatments Market By End Users (USD Billion, 2025-2035)

Hospitals & Clinics
Research Organization
Retail Pharmacies
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”